Commercialization of cell therapies – biopreservation’s make or break impact: an interview with Mike Rice

Mike Rice, CEO of NASDAQ traded BioLifeSolutions (WA, USA) explains the importance of biopreservation in commercializing regenerative medicine therapies and why funding for new cell-based therapies remains high.

Go to the profile of Freya Leask
Feb 09, 2017
1
0
Upvote 1 Comment

In this interview, Mike Rice, CEO of NASDAQ traded BioLifeSolutions (WA, USA) explains why effective biopreservation is critical for commercialization of regenerative medicine therapies, and why private, corporate and public funding for new cell-based therapies remains high.



Go to the profile of Freya Leask

Freya Leask

Editor and Community Manager, Future Science Group

I am the Editor and Community Manager of the RegMedNet and 3DMedNet communities, here to help users make the most of the website. I am passionate about digital and STM publishing, as well as regenerative medicine and medical 3D printing. Please get in touch if you have any queries or comments!
61 Contributions
27 Followers
12 Following

Please sign in or register for FREE to comment